AlloMap Molecular Expression Testing

New from XDx – Announcing…

AlloMap molecular expression testing is now available for cardiac transplants as early as 2 months post cardiac transplant!

For cardiac transplant patients, acute cellular rejection is most worrisome in the first months post transplant. As of Monday, August 21, 2006, AlloMap molecular expression testing is available to help you monitor patients as early as 2 months post cardiac transplant. When combined with patient assessment, AlloMap testing can provide the confidence you need to rule out acute cellular rejection.

Freedom from Future Rejection

A CARGO sub-study showed that patients with scores < 20 in the first 6 months post transplant were free from ACR ≥ 3A(2R) for the next 80 days (~12 weeks)¹.

¹ Data on File

Transplant Clinic

Patients & Families

Lab Professionals

Discover XDx

Transplant Clinic

Font Size:

AlloMap Testing Description

Developing AlloMap Testing

	Ongoing HTx Studies
	Other Transplant Organs Research

Billing & Reimbursement

Existing customers: click here to order supplies.

Applying Lessons from CARGO and AlloMap Testing to Other Organs

AlloMap testing is a multi-gene assay that assesses the activity of multiple molecular and cellular pathways involved in the alloimmune response. These processes are critical measures of immune activity and common processes involved in the immune response to all transplanted solid organs.

LARGO Study

The Lung Allograft Rejection Gene expression Observational (LARGO) study was initiated in April 2004 to examine the utility of molecular testing in lung post-transplant patient management. Fourteen centers from five countries and two continents are participating to investigate the utility of gene expression testing for management of lung transplant recipients.

Several thousand samples have been collected into the LARGO database. The LARGO study and database will provide an unparalleled resource for genomic and molecular diagnostic studies and development in lung transplantation. Assuming positive study results, XDx estimates to have a test available for clinical use in lung transplant recipients in the near future.